Co-Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
Co-Chair: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
General Session
8:00 AM – 9:00 AM EEST
Riney Research Symposium
Location: Trianti
Co-Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
Co-Chair: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
General Session
8:00 AM – 8:15 AM EEST
Liquid biopsy in myeloma to inform outcome and treatment decisions
Prevention and monitoring of infections with immunotherapies
Location: Trianti
Speaker: Joshua Richter, MD – Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
General Session
10:25 AM – 10:35 AM EEST
OA-07: Phase I Study of BCMA CAR-T Using Instant Manufacturing Platform or Traditional Production Process for Relapsed/Refractory Multiple Myeloma Therapy
Location: Trianti
Speaker: Hui Liu, LH – Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, China
General Session
10:35 AM – 10:45 AM EEST
OA-11: Utility of 18FDG-PET/CT for Risk Prediction in Relapsed/Refractory Multiple Myeloma Patients Undergoing CAR-T Cell Therapy: Analysis of Baseline and Early Assessment Scans After One and Three Months
Location: Trianti
Speaker: Luis-Esteban Tamariz-Amador, MD – Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IdiSNA
General Session
10:45 AM – 10:55 AM EEST
OA-51: Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study
OA-20: Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial.
Location: Trianti
Speaker: Alejandro Medina-Herrera, PhD – Departamento de Hematología, Hospital Universitario de Salamanca, (HUSA/IBSAL), Centro de Investigación del Cáncer-IBMCC (CSIC/USAL), CIBERONC
Oral Abstract Session
2:25 PM – 2:30 PM EEST
Summarize Abstract
Location: Trianti
Speaker: Samir Parekh, MD – Mount Sinai Medical Center, New York, NY, USA
Oral Abstract Session
2:30 PM – 2:35 PM EEST
Audience Q&A
Location: Trianti
Oral Abstract Session
2:35 PM – 2:45 PM EEST
OA-27: Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma
Location: Trianti
Speaker: Parvathi Sudha, MS (she/her/hers) – Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
Oral Abstract Session
2:45 PM – 2:50 PM EEST
Summarize Abstract
Location: Trianti
Speaker: Paola Neri, MD PhD – Arnie Charbonneau Cancer Research Institute, University of Calgary
Oral Abstract Session
2:50 PM – 2:55 PM EEST
Audience Q&A
Location: Trianti
Oral Abstract Session
2:55 PM – 3:05 PM EEST
OA-45: Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial
OA-48: Isatuximab plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Final Overall Survival Analysis
Location: Trianti
Speaker: Philippe Moreau, MD – University Hospital Hôtel-Dieu, Nantes, France
OA-52: Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
OA-53: Peripheral Blood and Bone Marrow Residual Disease Negativity to Identify a Subgroup of Newly Diagnosed Multiple Myeloma Patients with Long Term Disease Control
Location: Trianti
Speaker: Noemi Puig, MD, PhD – Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IBSAL)
Oral Abstract Session
4:05 PM – 4:10 PM EEST
Summarize Abstract
Location: Trianti
Speaker: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
OA-05: Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses
OA-47: Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy
Location: Skalkotas
Speaker: Salomon Manier, MD, PhD – Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
Oral Abstract Session
5:06 PM – 5:18 PM EEST
OA-08: GPRC5D-Targeted CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma Progressing after or Refractory to BCMA CAR-T cell therapy: Updated Results from a Phase 2 Clinical Trial
Location: Skalkotas
Speaker: Jieyun Xia, MD – The Affiliated Hospital of Xuzhou Medical University
Oral Abstract Session
5:18 PM – 5:30 PM EEST
OA-34: Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
OA-26: Single-cell analysis reveals disease induced perturbations of monocytes in the bone marrow and peripheral blood of multiple myeloma patients
Location: Mitropoulas
Speaker: Jian Cui – Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College
Oral Abstract Session
5:18 PM – 5:30 PM EEST
OA-03: Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
